INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo ENTEROLYTE Suspension

SCHEDULING STATUS:
Not scheduled

PROPRIETARY NAME
(and dosage form):

ENTEROLYTE Suspension

COMPOSITION:
Contains per 30 mL:

Kaolin                        6 000,0 mg
Pectin                        120,0 mg
Potassium chloride         41,4 mg
Sodium chloride         78,9 mg
Sodium lactate         86,4 mg
Preservatives 
Methylparaben 0,20% m/v
Propylparaben 0,02% m/v

PHARMACOLOGICAL CLASSIFICATION:
A.11.9 –Antidiarrhoeals

PHARMACOLOGICALACTION:
Enterolyte
exhibits intestinal adsorbent properties.

INDICATIONS:
Enterolyte
is indicated for use as an adjunct to rest, electrolyte-containing fluids and appropriate diet in the symptomatic treatment of mild to moderate acute diarrhoea.

CONTRA-INDICATIONS:
Intestinal obstruction. Hypersensitivity to any of the ingredients. The safety of Enterolyte for use during pregnancy and lactation has not been established. Not recommended for use in children under the age of 3 years.

WARNINGS:
The absorption of other agents from the gastro-intestinal tract can be reduced if administered concomitantly with Enterolyte.
The electrolytes contained in this product are not intended as fluid replacement therapy.

DOSAGE AND DIRECTIONS FOR USE:
Adults and adolescents: 60 to 80 mL three to four times daily
Children 12 years and over: 60 mL three to four times daily
Children 6 to under 12 years: 30 to 40 mL three to four times daily
Children 3 to under 6 years: 15 to 20 mL three to four times daily
If the symptoms persist for longer than 48 hours or the condition of the patient deteriorates, the treatment must be discontinued, and a doctor consulted. In the treatment of diarrhoea it is important that hydration be maintained by administering adequate fluids and electrolytes.
Shake the bottle before use.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Constipation may occur.
The adsorbant properties of kaolin may influence the gastro-intestinal absorption of other agents.
Potassium chloride may cause nausea, vomiting, diarrhoea, abdominal cramps and intestinal ulceration. Potassium solutions should be administered by mouth in well-diluted solutions. Potassium salts should be given cautiously to patients with renal or adrenal insufficiency, acute dehydration, or heat cramp. Sodium salts should be administered with caution to patients with congestive heart failure, peripheral or pulmonary oedema, impaired renal function, or pre-eclampsia.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Hyperkalaemia may occur after excessive intake of potassium chloride. Symptoms include paraesthesia of the extremeties, listlessness, mental confusion, weakness, paralysis, hypotension, cardiac arrhythmias, heartblock and cardiac arrest.
In hyperkalaemia, potassium-containing foods and medications must be discontinued and potassium-sparing diuretics withdrawn.
General adverse effects of excess sodium in the body include nausea, vomiting, diarrhoea, abdominal cramps, thirst, reduced salivation and lacrimation, sweating, fever, tachycardia, hypertension, renal failure, peripheral and pulmonary oedema, respiratory arrest, headache, dizziness, restlessness, irritability, weakness, muscle twitching and ridgidity, convulsions, coma and death. Excessive administration of sodium chloride causes hypernatraemia, the most serious effect of which is dehydration of internal organs, especially the brain. Excess chloride in the body may cause a loss of bicarbonate with an acidifying effect.
In the event of recent acute ingestion of sodium chloride, induction of emesis or gastric lavage should be carried out along with general symptomatic and supportive treatment.

IDENTIFICATION:
An off-white suspension with a characteristic banana odour and taste.

PRESENTATION:
Glass or plastic bottle containing 100 mL, 200 mL, and plastic bottle containing 2,5 L.

STORAGE INSTRUCTIONS:
Store below 25°C. Keep well-closed.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
E/11.9/1688

NAME AND BUSINESS ADDRESS OF APPLICANT:
The Premier Pharmaceutical Co. Ltd.
Adcock Ingram Park
17 Harrison Avenue, Bryanston Ext. 77
Private Bag X69, Bryanston 2021

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
31.08.1996

New addition to this site: April 2004
Source: Pharmaceutical Industry

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2004